The AP2B1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal human cell population derived from the A-549 lung adenocarcinoma cell line, featuring targeted disruption of the AP2B1 gene. This loss-of-function model enables investigation of the beta-1 subunit of the adaptor protein 2 (AP-2) complex in a robust epithelial cancer background. The polyclonal format provides a population-level representation of gene knockout, suitable for mirroring heterogeneous cellular responses in endocytosis and signaling studies.
The A-549 host cell line was originally established from a lung adenocarcinoma of a 58-year-old male and is widely employed as a model of alveolar type II epithelial cells. It is a cornerstone in research on lung cancer biology, drug metabolism, and respiratory disease pathophysiology. A-549 cells maintain key characteristics of pulmonary epithelium and offer a clinically relevant context for investigating oncogenic signaling and endocytic trafficking.
AP2B1 encodes the ??1 subunit of the heterotetrameric AP-2 adaptor complex, which is essential for clathrin-mediated endocytosis. The complex binds via its ??2 and ??2 subunits to tyrosine-based (YXX??) and dileucine sorting motifs on the cytoplasmic tails of transmembrane cargo receptors, including EGFR, TFRC, and LDLR, while the ??1 subunit recruits clathrin triskelia to initiate coated pit formation. Upstream regulators such as phosphatidylinositol-4,5-bisphosphate (PIP2) and kinases AAK1 and GAK control AP-2 membrane recruitment and conformational activation through phosphorylation. The complex cooperates with accessory proteins EPS15, DAB2, and HIP1R and interacts with dynamin (DNM2) for vesicle scission, thereby modulating receptor internalization, downstream signal transduction, and endocytic recycling.
In the A-549 lung adenocarcinoma context, AP2B1 knockout disrupts clathrin-dependent internalization pathways, providing a valuable system to dissect how endocytic trafficking influences oncogenic signaling, particularly EGFR and Notch pathway dynamics. Because A-549 cells are frequently used to study drug uptake and nanoparticle delivery, ablation of AP2B1 enables examination of how endocytic routes affect chemotherapeutic agent entry and response. This model also supports research into the role of endocytosis in epithelial polarity, receptor degradation kinetics, and the contribution of AP-2 mutations to neurodevelopmental disorders and cancer.
Typical applications include quantification of transferrin?CAlexa Fluor conjugate uptake to measure clathrin-mediated endocytosis efficiency, EGFR degradation assays following ligand stimulation, and cell surface biotinylation to assess receptor internalization rates. Researchers also employ this model in proliferation and migration assays to evaluate the impact of endocytic defects on tumor cell behavior, as well as RNA-seq profiling to uncover transcriptional consequences of AP2B1 loss. These polyclonal cells thus serve as a versatile platform for mechanistic studies and drug discovery efforts targeting endocytic machinery. For further information, please contact Ascent Research.
